Chongqing LUMMY Pharmaceutical Co., Ltd., headquartered in Chongqing, China, has grown into a high-tech pharmaceutical enterprise integrating R&D, manufacturing,sales and marketing since its establishment in 1999. In October 2009, LUMMY went public on Shenzhen GEM Stock market (Code: 300006). With the total assets of RMB 2.85 billion yuan and registered capital of RMB 812 million yuan, the company has developed an organizational structure comprising several subsidiaries and over 1500 employees.

In 2007, Chongqing first honored the “Top Ten Hi-Tech Innovative Enterprises” of the municipality, LUMMY was one of them and received the same honor for 2008 and 2009 in succession. In 2011, LUMMY was qualified as “Pioneering Enterprise of National Biological Industry Base” and “Hi-Tech Key Enterprise of National Torch Program”. The year of 2012 was a harvest year for LUMMY, which successively won the merits of “National Innovative Enterprise (Pioneer)”, “Best Industrial Enterprise of Chinese Pharmaceutical R&D and Product Lines”, “Chongqing Innovative Enterprise”, “Chongqing Technological Innovation Demonstrative Enterprise” and  “Chongqing Pioneering Unit of Intellectual Property Rights”. As a company of business credit, LUMMY scores three As (AAA) for its credit rating and received the honor of “Chongqing Outstanding Taxpaying Enterprise of Credibility and Integrity”. LUMMY, as the company’s trademark, was identified as “Chongqing Famous Trademark”. Some of its products were awarded the merits of “Chongqing Hi-Tech Product”, “Chongqing New Key Product”, “Chongqing Top Brand Product” as well as “Chongqing Famous Product”.

LUMMY underlines investment into R&D. Guided by an ideology that S&T innovation drives development, LUMMY has furnished nearly 200 million yuan for R&D in order to reinforce its R&D abilities, with two R&D platforms being organized, which are “Chongqing LUMMY Pharmaceutical Technology Center” and “LUMMY - Sichuan University United Laboratory”. LUMMY built “Chongqing Pharmaceutical Quality Control Engineering Technology Research Center” together with Sagent Pharmaceuticals (an American listed company) and was conferred the certification of “National Enterprise Technology Center”.LUMMY’s team of R&D consists of over 100 professional and experienced talents including those graduated from internationally renowned universities with PhD and master’s degrees. LUMMY has developed an integrated system from new drug design, screening, preclinical trials to clinical trials. Having been growing for nearly 20 years, LUMMY established an independent innovation R&D platform represented by nanotechnology such as lymphatic tracer, lymphatic-targeted chemotherapy and tumor-targeted chemotherapy, a science-to-technology transformation platform represented by micron/nano dispersion technology and sterile APIs manufacturing technology, and a first-generics platform represented by anti-infectives and pharmaceuticals used in specialty departments. With successfully applied-for patents numbering over 200,LUMMY ranks top in the list of new drug applications in Chongqing and even in China.

LUMMY was one of the enterprises that have first passed GMP/GSP certification in China. Its pharmaceutical manufacturing bases are located in Chayuan New District and Changshou Chemical Industry Park (Chongqing), Liuyang and Yiyang (Hu’nan Province), and Chengdu Hi-Tech Development Zone (Sichuan Province). LUMMY is also one of the domestic pharmaceutical enterprises that produce the most types of injection such as SVP, LVP, powder for injection as well as lyophilized powder for injection. Convinced that quality guarantees development, LUMMY is comprehensively promoting a management process in accordance with the cGMP. For several of its products, LUMMY has set stricter standards of quality control compared to the national standards. The fact that qualified rates of products for post-marketing random quality inspection have always maintained 100% wins LUMMY recognition and trust of the brand from its customers.


LUMMY never stops exploring new markets. Its wholly-owned subsidiary Chongqing LUMMY Pharmaceutical (Sales) Co., Ltd., which is a specialized sales company engaged in sales and marketing of LUMMY’s pharmaceutical products, has spread its business to 29 provinces and opened 25 liaison offices in first-tier cities like Beijing, Shanghai, Guangzhou, Chengdu and the Xinjiang Uygur Autonomous Region, with cross-country resources of VIP customers and marketing networks.

 

Adhering to the company philosophy of “quality is vitality, innovation is motivity and customers are resources” and the principle of “practical and innovative, people-oriented and pharmaceutical-engaged for common health”, LUMMY works hard to become afirst-class domestic pharmaceutical enterprise integrating R&D, manufacturing,sales and marketing that meets the international cGMP standard and national GMP/GSP standards. With reinforced R&D capability, advanced manufacturing technology and management level, LUMMY’s highly competitive sales team enjoys a good reputation among customers with its trustworthy products and is also striving for a certain market share for its products in variety. In return for shareholders’ support, LUMMY creates values and makes continuous efforts to improve human health!